Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?

Abstract

<jats:p> Background The rapid progress in oncology research requires numerous new scientific publications. This article aims to provide an overview of criteria-based imaging and response evaluation of lymphoma according to the current status of knowledge. In fact, common criteria for evaluating data, especially imaging response evaluation, are essential for comparability of studies. While criteria-based classifications of solid tumors have been established for some time, there are now increasing classifications of lymphoma diseases. The purpose of this review is to describe the development of criteria-based evaluation of lymphoma diseases with a special focus on imaging up to current guidelines.</jats:p><jats:p> Methods Literature review based on PubMed including the languages English and German was performed. This review article includes the most important criteria-based response evaluations of lymphoma published between January 1999 and July 2019.</jats:p><jats:p> Results and Conclusion The two latest classifications of response evaluation of lymphoma are: The Lugano classification, which has been steadily developed over the past 20 years and has been specially adapted to technical progress, as well as the evaluation method RECIL (Response Evaluation Criteria In Lymphoma), which is based on the RECIST (Response Evaluation Criteria in Solid Tumors) classification already established for solid tumors. Significant imaging components of both classifications are the anatomical measurement and measurement of the metabolic response of the manifestation of lymphoma using positron emission tomography (PET/CT).</jats:p><jats:p> Key Points: </jats:p><jats:p> Citation Format </jats:p>

Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology

“…This criterion was indeed designed to improve the standardization by eliminating the concept of SUV and increasing concordance among readers. [ 18 F]FDG PET/CT is currently considered an effective biomarker of lymphomas, and DS criteria became a gold standard included in the Lugano guidelines for the management of the disease as it gives clear clinical information with objectivity and reproducibility [25]. According to the Lugano criteria, the Deauville points match with different types of metabolic response based also on the comparison between baseline and post-therapy scans [26].…”